{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T19:54:34Z","timestamp":1789415674536,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007397","name":"Charles University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministry of Health of the Czech Republic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.jpba.2022.115154","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T20:45:19Z","timestamp":1668199519000},"page":"115154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["UHPLC-Orbitrap study of the first phase tacrine in vitro metabolites and related Alzheimer's drug candidates using human liver microsomes"],"prefix":"10.1016","volume":"224","author":[{"given":"M.","family":"Novak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Svobodova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Konecny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kuratkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Nevosadova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Prchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Korabecny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.M.","family":"Lauschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Soukup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Ku\u010dera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2022.115154_bib1","unstructured":"World Health Organization. World failing to address dementia challenge, 2021. \u3008https:\/\/www.who.int\/news\/item\/02\u201309-2021-world-failing-to-address-dementia-challenge\u3009. Accessed 16 June 2022."},{"key":"10.1016\/j.jpba.2022.115154_bib2","unstructured":"World Health Organization. Dementia: number of people affected to triple in next 30 years, 2019. \u3008https:\/\/www.who.int\/news\/item\/07\u201312-2017-dementia-number-of-people-affected-to-triple-in-next-30-years\u3009. Accessed 16 June 2022."},{"key":"10.1016\/j.jpba.2022.115154_bib3","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejmech.2017.07.070","article-title":"Tau protein aggregation in Alzheimer\u2019s disease: An attractive target for the development of novel therapeutic agents","volume":"139","author":"Jouanne","year":"2017","journal-title":"Eur. J. Med Chem."},{"key":"10.1016\/j.jpba.2022.115154_bib4","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7861\/clinmedicine.16-3-247","article-title":"Drug treatments in Alzheimer\u2019s disease","volume":"16","author":"Briggs","year":"2016","journal-title":"Clin. Med"},{"key":"10.1016\/j.jpba.2022.115154_bib5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.coph.2005.09.007","article-title":"Mechanism of action of memantine","volume":"6","author":"Johnson","year":"2006","journal-title":"Curr. Opin. Pharm."},{"key":"10.1016\/j.jpba.2022.115154_bib6","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41582-020-00454-9","article-title":"Aducanumab and the FDA - where are we now?","volume":"17","author":"Fillit","year":"2021","journal-title":"Nat. Rev. Neuro l"},{"key":"10.1016\/j.jpba.2022.115154_bib7","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/d41586-021-01763-9","article-title":"Controversial Alzheimer\u2019s drug approval could affect other diseases","volume":"595","author":"Mullard","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jpba.2022.115154_bib8","doi-asserted-by":"crossref","first-page":"14781","DOI":"10.15252\/emmm.202114781","article-title":"Aducanumab: a new phase in therapeutic development for Alzheimer\u2019s disease?","volume":"13","author":"Lalli","year":"2021","journal-title":"EMBO Mol. Med"},{"key":"10.1016\/j.jpba.2022.115154_bib9","first-page":"7","article-title":"Alzheimer\u2019s disease drug development pipeline: 2021","author":"Cummings","year":"2021","journal-title":"AD Transl. Res Clin. Inter."},{"key":"10.1016\/j.jpba.2022.115154_bib10","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nature20412","article-title":"The road to restoring neural circuits for the treatment of Alzheimer\u2019s disease","volume":"539","author":"Canter","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jpba.2022.115154_bib11","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/j.bmcl.2013.02.017","article-title":"Novel tacrine-related drugs as potential candidates for the treatment of Alzheimer\u2019s disease","volume":"23","author":"Romero","year":"2013","journal-title":"Bioorg. Med Chem. Lett."},{"key":"10.1016\/j.jpba.2022.115154_bib12","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0197-0186(97)00124-1","article-title":"Invited review: Cholinesterase inhibitors for Alzheimer\u2019s disease therapy: from tacrine to future applications","volume":"32","author":"Giacobini","year":"1998","journal-title":"Neurochem Int"},{"key":"10.1016\/j.jpba.2022.115154_bib13","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1600-0404.1992.tb04458.x","article-title":"Putative mechanisms of action of tacrine in Alzheimer\u2019s disease","volume":"85","author":"Adem","year":"1992","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.jpba.2022.115154_bib14","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.pnpbp.2017.01.003","article-title":"The pharmacology of tacrine at N -methyl- d -aspartate receptors","volume":"75","author":"Horak","year":"2017","journal-title":"Prog. NeuroPsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jpba.2022.115154_bib15","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3109\/00498259509061837","article-title":"Species variation in the bioactivation of tacrine by hepatic microsomes","volume":"25","author":"Madden","year":"1995","journal-title":"Xenobiotica"},{"key":"10.1016\/j.jpba.2022.115154_bib16","doi-asserted-by":"crossref","first-page":"168","DOI":"10.2165\/00023210-199504030-00002","article-title":"Tacrine-Induced Hepatotoxicity: Tolerability and Management","volume":"4","author":"Balson","year":"1995","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jpba.2022.115154_bib17","first-page":"39","article-title":"Tacrine transaminitis: potential mechanism","volume":"1","author":"Park","year":"1994","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.jpba.2022.115154_bib18","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S0090-9556(25)08177-2","article-title":"Bioactivation and irreversible binding of the cognition activator tacrine using human and rat liver microsomal preparations. Species difference","volume":"21","author":"Woolf","year":"1993","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jpba.2022.115154_bib19","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2174\/138920008784220619","article-title":"Possible role of hydroxylated metabolites of tacrine in drug toxicity and therapy of Alzheimer\u2019s disease","volume":"9","author":"Patocka","year":"2008","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.jpba.2022.115154_bib20","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jpba.2011.11.025","article-title":"Pharmacokinetics and brain dispositions of tacrine and its major bioactive monohydroxylated metabolites in rats","volume":"61","author":"Qian","year":"2012","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2022.115154_bib21","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1016\/j.bmcl.2017.04.006","article-title":"Cytochrome P450 binding studies of novel tacrine derivatives: Predicting the risk of hepatotoxicity","volume":"27","author":"McEneny-King","year":"2017","journal-title":"Bioorg. Med Chem. Lett."},{"key":"10.1016\/j.jpba.2022.115154_bib22","first-page":"130","article-title":"Biotransformation of the anticholinesterase agent, 9-amino-7-methoxy-1,2,3,4-tetrahydroacridine","volume":"40","author":"Patocka","year":"1991","journal-title":"Cesk Farm"},{"key":"10.1016\/j.jpba.2022.115154_bib23","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1358\/dof.1990.015.02.114543","article-title":"7-MEOTA","volume":"15","author":"Dejmek","year":"1990","journal-title":"Drug Future"},{"key":"10.1016\/j.jpba.2022.115154_bib24","doi-asserted-by":"crossref","first-page":"893","DOI":"10.2174\/1567205011310080011","article-title":"A Resurrection of 7-MEOTA: A Comparison with Tacrine","volume":"10","author":"Soukup","year":"2013","journal-title":"Curr. Alzheimer Res"},{"key":"10.1016\/j.jpba.2022.115154_bib25","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.neuropharm.2018.08.010","article-title":"7-Methoxyderivative of tacrine is a \u2018foot-in-the-door\u2019 open-channel blocker of GluN1\/GluN2 and GluN1\/GluN3 NMDA receptors with neuroprotective activity in vivo","volume":"140","author":"Kaniakova","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jpba.2022.115154_bib26","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1021\/jm990971t","article-title":"SAR of 9-amino-1,2,3,4-tetrahydroacridine-based acetylcholinesterase inhibitors: synthesis, enzyme inhibitory activity, QSAR, and structure-based CoMFA of tacrine analogues","volume":"43","author":"Recanatini","year":"2000","journal-title":"J. Med Chem."},{"key":"10.1016\/j.jpba.2022.115154_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114460","article-title":"7-phenoxytacrine is a dually acting drug with neuroprotective efficacy in vivo","volume":"186","author":"Kaniakova","year":"2021","journal-title":"Biochem Pharm."},{"key":"10.1016\/j.jpba.2022.115154_bib28","doi-asserted-by":"crossref","first-page":"552","DOI":"10.2174\/1567205015666171212105412","article-title":"Cholinesterase Inhibitor 6-Chlorotacrine - In Vivo Toxicological Profile and Behavioural Effects","volume":"15","author":"Misik","year":"2018","journal-title":"Curr. Alzheimer Res"},{"key":"10.1016\/j.jpba.2022.115154_bib29","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0021-9673(97)01117-5","article-title":"Capillary zone electrophoretic determination of some drugs against Alzheimer\u2019s disease","volume":"802","author":"Vargas","year":"1998","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpba.2022.115154_bib30","unstructured":"\u201eXenoTech H2600 and K5000\". \u3008https:\/\/www.xenotech.com\u3009 (accessed 5 May 2022)."},{"key":"10.1016\/j.jpba.2022.115154_bib31","doi-asserted-by":"crossref","first-page":"8985","DOI":"10.1021\/acs.jmedchem.5b01325","article-title":"Tacrine\u2013trolox hybrids: a novel class of centrally active, nonhepatotoxic multi-target-directed ligands exerting anticholinesterase and antioxidant activities with low in vivo toxicity","volume":"58","author":"Nepovimova","year":"2015","journal-title":"J. Med Chem."},{"key":"10.1016\/j.jpba.2022.115154_bib32","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1021\/ac990081l","article-title":"Comparative Study of Hydrocarbon, Fluorocarbon, and Aromatic Bonded RP-HPLC Stationary Phases by Linear Solvation Energy Relationships","volume":"71","author":"Reta","year":"1999","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2022.115154_bib33","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00216-008-1962-7","article-title":"High-performance liquid chromatography-tandem mass spectrometry in the identification and determination of phase I and phase II drug metabolites","volume":"391","author":"Holcapek","year":"2008","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jpba.2022.115154_bib34","unstructured":"BioTransformer 3.0. 2019. \u3008https:\/\/biotransformer.ca\/\u3009 (accessed 5 October 2021)."},{"key":"10.1016\/j.jpba.2022.115154_bib35","first-page":"985","article-title":"A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer\u2019s disease","volume":"271","author":"Knapp","year":"1994","journal-title":"Tacrine Study Group. JAMA"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708522005751?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708522005751?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:23:08Z","timestamp":1760001788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708522005751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":35,"alternative-id":["S0731708522005751"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2022.115154","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"UHPLC-Orbitrap study of the first phase tacrine in vitro metabolites and related Alzheimer's drug candidates using human liver microsomes","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2022.115154","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115154"}}